Table 2.
COVID-19 infection courses in enrolled patients.
| Group | Sex/age | Days of qRT PCR positivity | SARS-CoV-2 treatment | Vaccine dose | Infection course |
|---|---|---|---|---|---|
| group 3 | F/82 | 26 | MoAbs | 3D | mild |
| group 3 | M/41 | 8 | No | 3D | asymptomatic |
| group 4 | F/66 | 22 | MoAbs | 3D | mild |
| group 4 | F/65 | 41 | MoAbs | 3D | mild |
| group 1 | M/52 | 14 | MoAbs | 3D | mild |
| group 4 | F/79 | 25 | MoAbs | 3D | mild |
| group 4 | F/72 | 16 | MoAbs | 3D | mild |
| group 1 | F/47 | 37 | MoAbs | 3D | asymptomatic |
| group 1 | M/56 | 26 | MoAbs | 3D | mild |
| group 1 | M/33 | 11 | MoAbs | 3D | mild |
| group 4 | M/82 | 7 | Antiviral | 3D | mild |
| group 4 | M/60 | 8 | MoAbs | 3D | mild |
| group 4 | M/50 | 75 | MoAbs | 3D | mild |
| group 4 | M/55 | 14 | Antiviral | 3D | asymptomatic |
| group 4 | F/66 | 21 | MoAbs | 3D | asymptomatic |
| group 1 | F/45 | 26 | Antiviral | 3D | mild |
| group 3 | F/56 | 10 | No | 3D | mild |
| group 3 | F/47 | 30 | MoAbs | 3D | mild |
| group 3 | F/69 | 10 | MoAbs | 4D | mild |
| group 2 | M/60 | 17 | MoAbs | 4D | mild |
| group 1 | F/39 | 10 | No | 4D | mild |
| group 1 | F/66 | 10 | Antiviral | 4D | mild |
| group 4 | M/56 | 10 | Antiviral | 4D | mild |
| group 1 | F/74 | 9 | Antiviral | 4D | asymptomatic |
| group 1 | M/57 | 7 | Antiviral | 4D | mild |
| group 4 | M/50 | 10 | Antiviral | 4D | mild |
| group 3 | F/45 | 10 | Antiviral | 4D | mild |